Who else has licensed SpeechDx?

Siemens Healthineers became the first partner to non-exclusively license the dataset, and Callyope is the second licensee.

How is SpeechDx data collected and protected?

Participants record quarterly sessions on study-provided tablets, with audio encrypted and identifying details manually removed. Approved researchers access only the harmonized dataset in a controlled environment and cannot download or export it.

What is the size and scope of the SpeechDx study?

The program follows more than 2,000 participants over three years, with the program page describing 2,650 participants across global clinical sites. The cohort spans cognitively normal individuals through Alzheimer's dementia, as well as other conditions such as frontotemporal degeneration and Parkinson's disease.

Audio & SpeechAI in HealthcareTop Companies' AI MovesTop Companies AI12h agoOct 29, 2026, 06:30 JST

Eli Lilly licenses SpeechDx as third Alzheimer's data partner

Send on LINE

3 Key Points

What happened
The Alzheimer's Drug Discovery Foundation said on October 28, 2026 that Eli Lilly and Company has licensed SpeechDx, its longitudinal speech-and-biomarker dataset, to study speech as an Alzheimer's research tool. Lilly is the third licensee, after Siemens Healthineers and Callyope.
Why it matters
Lilly's move signals that industry partners see speech-based digital measures as a credible complement to established biomarkers in Alzheimer's research and drug development, according to the licensing organization.

WHO IT HITSPharmaceutical and diagnostics researchers working on Alzheimer's disease gain a licensed route to a large, harmonized speech-and-biomarker dataset, potentially reducing the data-collection burden for validating digital cognitive measures.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Get these free every morning

Context & Analysis

SpeechDx was launched in 2023 by the ADDF's Diagnostics Accelerator, which was created in 2018 with initial funders Leonard A. Lauder and Bill Gates to develop novel biomarkers for Alzheimer's disease and related dementias. The accelerator has since invested $100 million across 76 programs worldwide, and in March 2026 it announced a third phase backed by an additional $50 million, bringing the program's total to $150 million.

The dataset's design reflects the gap it was built to fill: the absence of datasets tracking how an individual's speech changes over time alongside biomarker-confirmed diagnoses and clinical outcomes. Participants undergo neuropsychological testing, MRI imaging and blood-biomarker amyloid status, with many also receiving PET imaging and cerebrospinal fluid status. Listed sites include Boston University, Emory University and the Barcelona Brain Health Initiative, with data collected in English, Spanish and Catalan.

Access to SpeechDx is non-exclusive, with the ADDF negotiating investment terms consistent with its venture philanthropy model. The first data became available to partners in Q1 2025, and quarterly releases continue as longitudinal collection proceeds.

FAQ

Who else has licensed SpeechDx?: Siemens Healthineers became the first partner to non-exclusively license the dataset, and Callyope is the second licensee.
How is SpeechDx data collected and protected?: Participants record quarterly sessions on study-provided tablets, with audio encrypted and identifying details manually removed. Approved researchers access only the harmonized dataset in a controlled environment and cannot download or export it.
What is the size and scope of the SpeechDx study?: The program follows more than 2,000 participants over three years, with the program page describing 2,650 participants across global clinical sites. The cohort spans cognitively normal individuals through Alzheimer's dementia, as well as other conditions such as frontotemporal degeneration and Parkinson's disease.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.